Stocks Health care MLTX
NASDAQ · Health careMoonLake Immunotherapeutics (MLTX)
It posted a net loss of $273.5M. In fiscal 2025 capital spending exceeded operating cash flow by $196M. At September 30, 2026 it held $379.7M in cash against $100M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about MoonLake Immunotherapeutics
- Net worth
- MoonLake Immunotherapeutics has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $381.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $196M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- MoonLake Immunotherapeutics's next report is expected around February 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What MoonLake Immunotherapeutics does
MoonLake Immunotherapeutics is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MLTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$227.3M | -$3.53 | -$196M |
| 2024 | n/a | -$118.9M | -$1.89 | -$117.1M |
| 2023 | n/a | -$36M | -$0.73 | -$43.1M |
| 2022 | n/a | -$50M | -$1.70 | -$55.9M |
| 2021 | n/a | -$4.5M | -$0.31 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What MoonLake Immunotherapeutics has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- September 30, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 10, 2026
- August 10, 2026
- August 10, 2026
Insider trades
What the people running MoonLake Immunotherapeutics did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 27, 2026 | Reich KristianChief Scientific Officer | Soldpre-planned (10b5-1), indirect | 1,100 | $22K |
| July 22, 2026 | Reich KristianChief Scientific Officer | Soldpre-planned (10b5-1), indirect | 2,448 | $49K |
| July 21, 2026 | Reich KristianChief Scientific Officer | Soldpre-planned (10b5-1), indirect | 50,000 | $1M |
| July 20, 2026 | Reich KristianChief Scientific Officer | Soldpre-planned (10b5-1), indirect | 43,700 | $877.9K |
| July 15, 2026 | Reich KristianChief Scientific Officer | Soldpre-planned (10b5-1), indirect | 16,105 | $322.3K |
| July 10, 2026 | Santos da Silva JorgeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 68,289 | $1.4M |
| July 9, 2026 | Santos da Silva JorgeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 33,936 | $679.1K |
| July 1, 2026 | Santos da Silva JorgeChief Executive Officer, Director | Soldpre-planned (10b5-1) | 47,775 | $956.9K |
Who owns MLTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bvf Partners L P13D, may seek influence with 10 related filers | 19.7% | June 29, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 9.74% | August 14, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 5.3% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 173 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bvf Inc | 16,001,284 | 0 |
| Deep Track Capital, LP | 6,999,025 | +590,162 |
| D. E. Shaw & Co., Inc. | 3,365,507 | +974,846 |
| Cormorant Asset Management, LP | 3,205,433 | -1,275,000 |
| Jupiter Topco LLC | 3,085,906 | new |
| Logos Global Management LP | 2,675,000 | +1,175,000 |
| Weiss Asset Management LP | 2,581,813 | +873,485 |
| Citadel Advisors LLC | 1,972,893 | +649,165 |
| Two Sigma Investments, LP | 1,715,349 | +593,037 |
| Mpm Bioimpact LLC | 1,606,967 | -204,115 |
| Jpmorgan Chase & Co | 1,386,422 | +297,908 |
| Vivo Capital, LLC | 1,400,000 | +400,000 |
| Point72 Asset Management, L.P. | 1,158,732 | -209,786 |
| BlackRock, Inc. | 1,094,791 | +72,940 |
| Balyasny Asset Management L.P. | 912,715 | -152,895 |
| Great Point Partners LLC | 855,813 | +355,813 |
| Jane Street Group, LLC | 853,386 | +399,761 |
| Candriam S.C.A. | 769,766 | -48,360 |
| Bank of America Corp | 751,897 | +27,103 |
| Arrowstreet Capital, Limited Partnership | 750,777 | +680,637 |
Insiders
4 insiders reported holding 7,676,153 shares in total, about $96.9M at the last price.
| Holder | Shares |
|---|---|
| Santos da Silva JorgeChief Executive Officer, Director | 2,774,893 |
| Reich KristianChief Scientific Officer | 2,746,5872,711,198 held indirectly |
| Bodenstedt MatthiasChief Financial Officer | 1,115,435 |
| Bvf Partners L P/IlDirector, 10% owner | 1,039,238 |
Questions about MLTX
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics is a company in the Health care sector, listed on NASDAQ as MLTX. Its shares trade on NASDAQ under the ticker MLTX.
What is MoonLake Immunotherapeutics's net worth?
MoonLake Immunotherapeutics has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $381.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is MoonLake Immunotherapeutics profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $273.5M.
When did MoonLake Immunotherapeutics last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is MoonLake Immunotherapeutics's next earnings report?
MoonLake Immunotherapeutics's next report is expected around February 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MLTX with
Follow MLTX
Get an email when MoonLake Immunotherapeutics files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values MoonLake Immunotherapeutics tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.